Clinical trial
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in…
NCT00400348 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00400348 |
|---|---|
| Title | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer |
| Official title | A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Panzem Nanocrystal Colloidal Dispersion (NCD) |
| Enrollment | 18 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Nov 16, 2006 |
| Last update posted | Nov 25, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: